Press releases

Boston Scientific (NYSE: BSX) has received United States (U.S.) Food and Drug Administration (FDA) approval and CE Mark for the AngioJet™ ZelanteDVT™ thrombectomy catheter to treat deep vein...

Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Oppenheimer 26th Annual Healthcare Conference on December 8, in New York City. Susie Lisa, vice president, Investor...

Boston Scientific (NYSE: BSX) today announced that the first implants of the WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device – the latest generation of the WATCHMAN Device –...

Boston Scientific (NYSE: BSX) has received a score of 100 percent on the 2016 Corporate Equality Index (CEI), a national benchmarking survey and report on corporate policies and practices related...

Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Piper Jaffray 27th Annual Healthcare Conference on December 1, in New York City. Jeff Mirviss, senior vice president...

Boston Scientific (NYSE: BSX) has entered into a definitive agreement to acquire the interventional radiology portfolio of CeloNova Biosciences, a San Antonio-based developer of endovascular and...

Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Canaccord Genuity 9th Annual Medical Technology and Diagnostics Forum on November 19, in New York City. David Pierce,...

Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Stifel Healthcare Conference on November 17, in New York City. Susie Lisa, vice president, Investor Relations, will...

Boston Scientific Corporation (NYSE: BSX) generated sales of $1.888 billion during the third quarter ended September 30, 2015, compared to the company's guidance range for the quarter of $1.790 to...

Boston Scientific Corporation (NYSE: BSX) today announced that it has closed on an additional round of financing with MValve Technologies Ltd., a developer of a percutaneous mitral valve...

Boston Scientific (NYSE: BSX) this week announced the start of the Boston Scientific Connected Patient Challenge, an open innovation contest designed to encourage advancements in the use of remote...

Boston Scientific (NYSE: BSX) today announced key data presentations spanning its broad interventional cardiology, structural heart and peripheral interventions portfolios to be shared at the 27th...

Boston Scientific (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval for the SYNERGY™ Bioabsorbable Polymer Drug-Eluting Stent System (BP-DES) for the treatment of...

Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the third quarter ended September 30, 2015 on Wednesday, October...

Boston Scientific Corporation (NYSE: BSX) announced today the launch of the Captivator™ EMR Device for Endoscopic Mucosal Resection (EMR), a minimally invasive alternative to an esophagectomy, a...

New 12-month clinical trial outcomes assessing the safety and performance of the Boston Scientific (NYSE: BSX) Eluvia™ Drug-Eluting Vascular Stent System reflect a primary patency rate1 of more...

Boston Scientific (NYSE: BSX) has received CE Mark for the Vercise™ Primary Cell (PC) Deep Brain Stimulation (DBS) System. The Vercise PC System is intended to provide precise neural targeting...

Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 2015 Morgan Stanley Global Healthcare Conference on September 17, in New York City. Mike Mahoney, chief executive...

Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 2015 Wells Fargo Healthcare Conference on September 9 in Boston, MA. Mike Mahoney, chief executive officer, and Dan...

Boston Scientific Corporation (NYSE: BSX) has received CE Mark on magnetic resonance imaging (MRI) conditional labeling for the current family of EL (Extended Longevity) and MINI implantable...

Boston Scientific Corporation (NYSE: BSX) has received Food and Drug Administration (FDA) approval for the Innova™ Vascular Self-Expanding Stent System, an advanced treatment option for patients...

Boston Scientific Corporation (NYSE: BSX) has closed on the previously announced agreement with Endo International plc (NASDAQ: ENDP) (TSX: ENL) to purchase American Medical Systems' (AMS) Men's...

Boston Scientific (NYSE: BSX) has become a significant shareholder and will become the exclusive worldwide sales and marketing representative for Preventice Solutions for cardiology-related...

Boston Scientific Corporation (NYSE: BSX) generated sales of $1.843 billion during the second quarter ended June 30, 2015, compared to the company's guidance range for the quarter of $1.800 to...

MARLBOROUGH, Mass. (July 22, 2015) – Boston Scientific (NYSE: BSX) announces CE Mark and FDA clearance for the Safari2™ Pre-Shaped Guidewire, a new and enhanced version of the Safari...